The goal of this clinical trial is to assess the feasibility of ceftolozane/tazobactam (C/T) administered on an outpatient parenteral antibiotic therapy programme to patients with a current infective exacerbation of bronchiectasis or cystic fibrosis related to pseudomonas aeruginosa or burkholderia cepacia spp. organisms. The main question\[s\] it aims to answer are: * Is C/T effective, safe, well-tolerated and able to induce clinical and microbiologic response? * What are mechanisms of antimicrobial resistance are induced by administration of C/T?
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The feasibility of the use of ceftolozane/tazobactam given via continuous infusion in an OPAT setting for the treatment of acute exacerbations of CF and bronchiectasis.
Timeframe: Day 0 to day 90 post commencement of intervention.